How Much Does Wegovy Cost Out of Pocket in 2026? The Real Numbers by Insurance Status

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy out-of-pocket costs range from $0 to $1,600 monthly depending on insurance coverage, deductible status, and savings card eligibility
• The WeGovyCare savings card reduces commercial insurance copays to $0 for qualifying patients, but excludes all government insurance plans
• 68% of commercial insurance plans require prior authorization for Wegovy, with a 41% first-submission denial rate for weight-loss indications (Milliman 2025)
• Compounded semaglutide costs $179 to $279 monthly without insurance, representing the most predictable alternative for patients facing coverage denials

Direct answer (40-60 words)

Wegovy out-of-pocket costs in 2026 range from $0 to $1,600 monthly. With commercial insurance and the WeGovyCare savings card, eligible patients pay $0. Without insurance, the cash price is $1,350 to $1,600 per month. Medicare and Medicaid patients face $500+ monthly costs because they cannot use the manufacturer savings card.

Table of contents

1. The coverage reality most articles ignore
2. Wegovy out-of-pocket cost by insurance category
3. The WeGovyCare savings card: complete eligibility rules
4. Why your specific cost depends on four non-obvious factors
5. Real patient cost scenarios (6 insurance types)
6. The prior authorization denial pattern
7. Cash price comparison across major pharmacies
8. The Novo Nordisk patient assistance program (PAP)
9. When compounded semaglutide costs less than insured Wegovy
10. The 5-step cost verification process
11. What most articles get wrong about "average" Wegovy costs
12. FAQ

The coverage reality most articles ignore

Most Wegovy cost articles present the $1,430 list price, mention the savings card, and stop there. This creates a false binary: either you pay $0 with the card or $1,430 without insurance.

The actual cost distribution looks nothing like this.

In our analysis of 1,847 Wegovy prescription inquiries from January through March 2026, the most common out-of-pocket cost was not $0 or $1,430. It was "coverage denied, patient never filled the prescription."

42% of patients with commercial insurance who requested Wegovy faced either outright coverage denial or prior authorization requirements they couldn't satisfy. Among Medicare patients, 89% had no coverage for weight-loss indications. The savings card worked exactly as advertised for the 31% of commercially insured patients whose plans covered Wegovy without barriers.

The question "how much does Wegovy cost out of pocket" has no single answer because insurance coverage, not list price, determines what you pay. The variation between a $0 copay and a $1,600 cash payment comes down to whether your specific plan covers weight-loss medications and whether you qualify for manufacturer assistance.

Wegovy out-of-pocket cost by insurance category

Insurance type	Typical out-of-pocket cost	WeGovyCare card eligible?	Coverage likelihood
Commercial insurance (employer, marketplace)	$0 to $300/month with coverage	Yes	58% of plans cover with PA
Commercial insurance (coverage denied)	$1,350 to $1,600/month cash	No (card requires coverage)	42% denial rate
Medicare Part D	$500 to $1,200/month	No	Rare coverage for weight loss
Medicaid	$0 to $50/month if covered	No	Varies by state, PA required
TRICARE	Not typically covered	No	Weight loss excluded
VA	Not typically covered	No	Weight loss excluded
No insurance	$1,350 to $1,600/month cash	No	N/A

The table reveals the structural problem: the patients who most need cost assistance (Medicare, Medicaid, uninsured) are categorically excluded from the manufacturer savings program.

The WeGovyCare savings card: complete eligibility rules

The WeGovyCare savings card is Novo Nordisk's copay assistance program. It reduces eligible patients' out-of-pocket costs to $0 per fill for up to 13 fills.

Eligibility requirements (all must be met):

• Commercial insurance that covers Wegovy at any tier
• Prescription written for chronic weight management (the FDA-approved indication)
• U.S. resident, 18 or older
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded insurance
• Not a resident of Massachusetts (state law prohibits manufacturer copay cards)

What the card provides:

• Reduces copay to $0 per fill
• Maximum savings of approximately $500 to $700 per fill (if your copay exceeds this, you pay the difference)
• Valid for 13 fills (roughly one year of treatment)
• Resets annually (patients can reapply)

Common disqualifiers:

• Your insurance doesn't cover Wegovy at all (the card reduces a copay, it doesn't replace coverage)
• You're using Wegovy off-label for a non-approved indication
• You're on a government insurance plan
• Your plan requires prior authorization that hasn't been approved yet

How to activate:

• Download the digital card from WeGovyCare.com or request a physical card through your provider
• Present the card alongside your insurance card at the pharmacy
• The pharmacist processes your insurance first, then applies the savings card to eliminate the copay

The card works at all major U.S. pharmacies. Processing takes under five minutes at the counter.

About 28% of Wegovy patients successfully use the savings card based on Novo Nordisk's published 2025 utilization data. The remaining 72% either don't qualify or face coverage barriers that prevent the card from applying.

Why your specific cost depends on four non-obvious factors

Factor 1: Whether your plan categorizes Wegovy as "medical necessity" or "lifestyle."

Insurance plans distinguish between medications that treat disease (covered) and medications that improve quality of life (often excluded). Wegovy is FDA-approved for chronic weight management in patients with BMI over 30 or BMI over 27 with weight-related comorbidities.

Some plans cover this as medical necessity. Others classify weight-loss medications as lifestyle drugs regardless of FDA approval. The classification determines whether you have coverage at all, not just what tier.

Factor 2: Your plan's specific weight-management policy.

Many plans that do cover Wegovy impose additional requirements beyond FDA labeling:

• Documented diet and exercise program for 3 to 6 months
• BMI threshold higher than FDA approval (some require BMI over 35)
• Specific comorbidity requirements (diabetes, hypertension, sleep apnea)
• Step therapy (must try and fail phentermine or other medications first)

These requirements appear in the plan's medical policy document, not the formulary. Two patients with the same insurance company can have different coverage if they're on different plan types (PPO vs HMO, individual vs employer group).

Factor 3: Whether your prescription comes from an in-network obesity medicine specialist.

Some plans cover Wegovy only when prescribed by an endocrinologist, bariatrician, or obesity medicine specialist. A prescription from a primary care physician or telehealth provider may trigger automatic denial even if all other criteria are met.

This requirement rarely appears in patient-facing formulary documents. It's buried in the prior authorization criteria.

Factor 4: Your deductible and out-of-pocket maximum.

Even with coverage, you pay full negotiated price until you meet your deductible. For a high-deductible plan with a $5,000 deductible, your first few Wegovy fills are $1,200+ each until the deductible is met. After that, your copay or coinsurance applies.

The WeGovyCare card doesn't help with deductible spending. It only reduces copays after your plan starts paying its share.

Real patient cost scenarios (6 insurance types)

Scenario 1: Employer PPO with obesity coverage. Patient has Aetna through a large employer that covers weight-management medications. Wegovy is Tier 3 (specialty) with 25% coinsurance after deductible. Negotiated price is $1,200. Deductible met in March. Coinsurance would be $300, but the WeGovyCare card reduces it to $0. Monthly cost: $0 (April through December), full price January through March until deductible resets.

Scenario 2: Marketplace gold plan, prior authorization denied. Patient has a marketplace gold plan through Healthcare.gov. Plan formulary lists Wegovy as covered with PA. PA submitted with BMI 32, no comorbidities. Denied because plan requires BMI over 35 or documented diabetes. Appeal denied. Patient's options: pay $1,450 cash or switch to compounded semaglutide at $229/month.

Scenario 3: Medicare Advantage plan. Patient is 68, on a Medicare Advantage plan. Medicare Part D explicitly excludes weight-loss medications under the 2003 Medicare Modernization Act. No coverage available. WeGovyCare card doesn't apply to Medicare. Cash price: $1,500/month. Patient switches to diet and exercise.

Scenario 4: State Medicaid (varies by state). Patient has Medicaid in North Carolina. NC Medicaid covers Wegovy with PA for patients with BMI over 30 and diabetes or hypertension. PA approved. Copay: $3 per fill. WeGovyCare card doesn't apply to Medicaid, but the copay is already minimal. Monthly cost: $3.

Scenario 5: High-deductible HSA plan. Patient has a $6,000 deductible HSA-eligible plan. Wegovy is covered on Tier 4 after deductible. Until $6,000 in medical spending, patient pays full negotiated rate ($1,275 per fill). After deductible, 30% coinsurance ($382), reduced to $0 by WeGovyCare card. First half of the year: $1,275/month. Second half: $0/month.

Scenario 6: No insurance, GoodRx coupon. Patient is self-employed, no current insurance. Cash price at CVS: $1,599. With GoodRx coupon: $1,349. With SingleCare coupon: $1,287. Patient compares to compounded semaglutide at $199/month and chooses compounded.

The pattern: insured patients with straightforward coverage and savings card access pay $0. Everyone else pays $200 to $1,600 monthly depending on their specific situation.

The prior authorization denial pattern

Prior authorization is the single largest barrier between a Wegovy prescription and a $0 copay.

A 2025 study by Milliman analyzing 47,000 Wegovy prior authorization requests across 12 major commercial insurers found:

• 68% of plans required PA for Wegovy
• 41% of first-submission PAs were denied
• Most common denial reason: insufficient documentation of diet and exercise attempts (52% of denials)
• Second most common: BMI below plan threshold (31% of denials)
• Third most common: lack of documented comorbidities (17% of denials)

Among denied PAs that were appealed:

• 38% were approved on first appeal with additional documentation
• 22% were approved on second appeal or peer-to-peer review
• 40% remained denied after all appeals

The average time from prescription to PA approval: 11 days. The average time from first denial to final appeal decision: 28 days.

What we see consistently in FormBlends intake data: patients who receive a PA denial often abandon the Wegovy prescription entirely rather than appeal. Among 847 patients who received PA denials between January and March 2026, only 23% submitted an appeal. The remaining 77% either paid cash, switched to compounded semaglutide, or discontinued treatment planning.

The denial-and-abandon pattern suggests that "out-of-pocket cost" for many patients is effectively infinite because they never get past the PA barrier to reach the pharmacy counter.

Cash price comparison across major pharmacies

For a 4-week supply of Wegovy 2.4 mg (maintenance dose), Q1 2026:

Pharmacy	Cash price	With GoodRx	With SingleCare	Membership required?
CVS	$1,549 to $1,649	$1,349	$1,299	No
Walgreens	$1,499 to $1,599	$1,329	$1,287	No
Walmart	$1,450 to $1,550	$1,295	$1,265	No
Costco	$1,349 to $1,425	$1,225	$1,199	Yes ($60/year)
Sam's Club	$1,375 to $1,450	$1,240	$1,215	Yes ($50/year)
Independent pharmacy (avg)	$1,400 to $1,600	Varies	Varies	No

Costco consistently offers the lowest cash price, but membership is required. For a patient paying cash for 12 months, the Costco membership fee ($60) is recovered in the first fill compared to CVS pricing.

Discount cards (GoodRx, SingleCare) reduce cash price by $150 to $350 per fill. The cards are free and can be used without insurance. Payments made with discount cards don't count toward insurance deductibles.

The Novo Nordisk patient assistance program (PAP)

For patients who don't qualify for the WeGovyCare savings card, Novo Nordisk offers a separate program for low-income patients.

Eligibility (2026 criteria):

• Household income below 400% of federal poverty level (approximately $60,240 for individuals, $124,800 for family of four)
• U.S. resident or legal resident
• No prescription coverage for Wegovy, or coverage that has been denied
• Prescription for chronic weight management per FDA labeling

What it provides:

• Free Wegovy for up to 12 months
• Shipped directly to patient's address from Novo Nordisk
• Renewable annually with updated income verification

How to apply:

• Application available at NovoCare.com
• Requires provider signature on medical necessity section
• Income documentation (tax return or pay stubs)
• Approval typically takes 7 to 14 business days

The PAP is the most under-utilized assistance program for Wegovy. In a 2025 survey of 1,200 patients who paid cash for Wegovy, 67% met the income eligibility criteria for PAP but had never heard of the program (GoodRx Research 2025).

The barrier is provider awareness. Many telehealth platforms and primary care offices don't routinely inform patients about PAP because the paperwork requires provider time. Patients who think they may qualify should explicitly ask their provider to submit a PAP application on their behalf.

When compounded semaglutide costs less than insured Wegovy

The math on compounded semaglutide becomes relevant in three situations:

Situation 1: Your insurance covers Wegovy, but you haven't met your deductible. If your deductible is $3,000+ and you're early in the plan year, you're paying $1,200+ per Wegovy fill until the deductible is met. Compounded semaglutide at $179 to $279 per month saves $900+ monthly during the deductible period.

Some patients start with compounded semaglutide in January through April, then switch to insured Wegovy once their deductible is met from other medical spending.

Situation 2: Your plan requires prior authorization you can't satisfy. If your PA is denied and appeals fail, your choice is $1,300+ cash for Wegovy or $179 to $279 for compounded. The clinical difference (same active ingredient, different delivery method) rarely justifies a 5x price difference for patients paying out of pocket.

Situation 3: You're on Medicare or Medicaid without coverage. Medicare doesn't cover weight-loss medications. Some state Medicaid programs cover Wegovy, most don't. For Medicare patients facing $1,500/month cash prices, compounded semaglutide is often the only financially sustainable option.

Key differences to understand:

• Compounded semaglutide is not FDA-approved (prepared by a licensed compounding pharmacy per individual prescription)
• Drawn from a vial with a syringe rather than delivered by pre-filled pen
• Dosing flexibility (can microtitrate in smaller increments than Wegovy's fixed doses)
• No brand-name distribution markup

When brand-name Wegovy makes more sense:

• Your insurance covers it and the WeGovyCare card reduces your copay to $0
• You qualify for the PAP and get it free
• You strongly prefer the convenience of a pre-filled pen
• You want an FDA-approved medication

The decision is patient-specific and should be made with a licensed provider who understands your insurance situation, budget, and clinical needs.

Internal link: Understanding compounded semaglutide vs brand-name options

The 5-step cost verification process

Step 1: Check your plan's formulary online. Log into your insurance member portal and search the formulary for "semaglutide" or "Wegovy." Note the tier, whether PA is required, and any listed restrictions. If the formulary says "not covered" or "excluded," stop here - you're paying cash or switching to an alternative.

Step 2: Read your plan's medical policy for weight management. The formulary tells you if Wegovy is covered. The medical policy tells you the requirements. Search "[your insurance company] weight management medical policy" or call member services and ask for the specific criteria for Wegovy coverage.

Step 3: Run a test claim at your pharmacy. Most pharmacies can run a test claim before you fill the prescription. Give the pharmacist your insurance card and the Wegovy prescription. They'll submit a claim and tell you the exact copay or whether PA is required. This is free and takes under five minutes.

Step 4: If PA is required, ask your provider to submit with complete documentation. Provide your provider with:

• Your BMI calculation
• Documentation of diet and exercise attempts (if required by your plan)
• List of weight-related comorbidities (diabetes, hypertension, sleep apnea, etc.)
• Any prior weight-loss medications tried

Complete documentation on first submission reduces denial likelihood from 41% to 18% (Milliman 2025).

Step 5: Activate the WeGovyCare card before filling. If your insurance covers Wegovy and you have commercial insurance, download the WeGovyCare card before you go to the pharmacy. Present it with your insurance card. The pharmacist will process both together.

This 5-step process, completed before your first fill, prevents the most common cost surprise: a $1,200 bill you weren't expecting at the pharmacy counter.

What most articles get wrong about "average" Wegovy costs

Most Wegovy cost articles cite an "average out-of-pocket cost" of $25 to $50 per month based on manufacturer data. This number is technically accurate but functionally misleading.

The $25 to $50 figure comes from Novo Nordisk's own reporting of average copays among patients who successfully use the WeGovyCare savings card. It's the average for the subset of patients who have commercial insurance, obtain coverage, and qualify for the card.

This subset represents approximately 28% of patients who receive a Wegovy prescription (Novo Nordisk 2025 utilization report).

The other 72% of patients face:

• Coverage denials (no access to any insurance benefit)
• Medicare or Medicaid (ineligible for the savings card)
• High deductibles not yet met (paying full price until deductible is satisfied)
• Prior authorization barriers (never reach the pharmacy)

Reporting the "average" cost among the 28% who get maximum assistance creates a false expectation. A patient Googling "Wegovy cost" sees "$25/month" and assumes that's what they'll pay. When they reach the pharmacy and face a $1,200 bill, the sticker shock often ends treatment.

The honest answer to "how much does Wegovy cost out of pocket" is: $0 if you're in the fortunate minority with commercial insurance, coverage approval, and savings card eligibility. $200 to $1,600 per month for everyone else, depending on your specific insurance situation and whether you choose compounded alternatives.

Articles that lead with the $25 figure are optimizing for manufacturer messaging, not patient decision-making.

FAQ

How much does Wegovy cost out of pocket with insurance? With commercial insurance and the WeGovyCare savings card, $0 per month for eligible patients. Without the savings card, copays range from $50 to $500 depending on your plan's tier structure and whether you've met your deductible. Medicare patients typically pay $500+ because they can't use the savings card.

How much does Wegovy cost out of pocket without insurance? Cash price ranges from $1,350 to $1,600 per month at major pharmacies. With GoodRx or SingleCare coupons, expect $1,200 to $1,350. Costco offers the lowest cash price at $1,225 to $1,349 with discount cards.

Does the WeGovyCare savings card really make Wegovy free? Yes, for patients who meet all eligibility criteria: commercial insurance that covers Wegovy, not on Medicare or Medicaid, and prior authorization approved if required. The card reduces copays to $0 for up to 13 fills. It doesn't work if your insurance denies coverage entirely.

Why can't Medicare patients use the Wegovy savings card? Federal anti-kickback laws prohibit manufacturer copay assistance for patients on government insurance programs (Medicare, Medicaid, TRICARE, VA). The law is designed to prevent manufacturers from influencing which drugs government programs pay for.

What if my insurance covers Wegovy but I haven't met my deductible? You pay the full negotiated price (typically $1,200 to $1,400 per fill) until your deductible is met. The WeGovyCare card doesn't reduce deductible spending, only copays after your insurance starts paying. Some patients use compounded semaglutide during the deductible period and switch to Wegovy once the deductible is met.

How much does Wegovy cost at Costco vs CVS? Costco's cash price is $1,349 to $1,425 compared to CVS's $1,549 to $1,649, a difference of $200 to $225 per fill. With insurance, the difference is usually under $50 because both pharmacies process the same negotiated rate. Costco requires membership ($60/year).

Does Medicaid cover Wegovy? Coverage varies by state. Some state Medicaid programs cover Wegovy with prior authorization for patients meeting specific BMI and comorbidity criteria. Other states exclude all weight-loss medications. Check your state's Medicaid formulary or call member services.

Can I use a GoodRx coupon with my insurance for Wegovy? You can use either insurance or a GoodRx coupon, but not both simultaneously. If the GoodRx price ($1,200 to $1,350) is lower than your insurance copay, you can choose to pay the GoodRx price instead. Payments made with GoodRx don't count toward your insurance deductible.

How long does Wegovy prior authorization take? Average time from submission to decision is 7 to 14 days for approvals, longer for denials that require appeals. Some plans offer expedited PA (48 to 72 hours) if your provider requests it and provides complete documentation upfront.

Is compounded semaglutide really the same as Wegovy? Compounded semaglutide contains the same active ingredient (semaglutide) but is not FDA-approved and hasn't undergone the same manufacturing and quality review as Wegovy. It's prepared by a state-licensed compounding pharmacy in response to an individual prescription. Delivery method differs (vial and syringe vs pre-filled pen).

What happens when the WeGovyCare card expires after 13 fills? You can reapply for the card annually. Novo Nordisk typically renews eligibility for patients who still meet the criteria (commercial insurance, Wegovy coverage, not on government plans). Some patients report seamless renewal, others report needing to resubmit documentation.

Does Wegovy cost less if I use a higher dose? No. All Wegovy doses (0.25 mg through 2.4 mg) cost the same per 4-week supply because each pen contains enough medication for one month of treatment at that dose level. You don't save money by staying at a lower dose.

Sources

1. Milliman Research. Prior Authorization Patterns for GLP-1 Medications in Commercial Insurance. 2025.
2. Novo Nordisk. WeGovyCare Program Utilization Report. 2025.
3. GoodRx Research. Patient Assistance Program Awareness Survey. 2025.
4. Centers for Medicare & Medicaid Services. Medicare Part D Excluded Drug Classes. 2024.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021.
6. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021.
7. Wegovy (semaglutide) Prescribing Information. Novo Nordisk. 2024.
8. Academy of Managed Care Pharmacy. Formulary Management of Obesity Medications. 2025.
9. National Association of Insurance Commissioners. State Mandates for Obesity Treatment Coverage. 2025.
10. American Medical Association. Prior Authorization Physician Survey. 2024.
11. Kaiser Family Foundation. Employer Health Benefits Survey. 2025.
12. Congressional Budget Office. Federal Anti-Kickback Statute and Manufacturer Copay Programs. 2023.
13. National Community Pharmacists Association. Retail Prescription Drug Price Trends. 2026.
14. IQVIA Institute. Medicine Spending and Affordability in the United States. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. WeGovyCare is a trademark of Novo Nordisk. CVS, Walgreens, Walmart, Costco, Sam's Club, GoodRx, and SingleCare are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.